Publication Topic

Wallace E, Sacks NC, Cyr P, Baker-Wagner M. An observational cohort analysis on the economic impact of chronic kidney disease in patients with fabry disease. Poster presentation, ISPOR Annual International Meeting, Virtual, May 2021.

Sacks NC, Healey B, Cyr PL, Slocomb T, James E, Beggs A, Graham RJ. Healthcare resource use and expenditures in patients with x-linked myotubular myopathy (XLMTM). Poster presentation, ISPOR 25th Annual International Meeting, Orlando, FL, April 2021.

Panattoni L, Hernandez J, Liu Y, Sacks NC, Higham R, Stephenson B, Armstrong A. Initial treatment patterns for newly diagnosed, commercially insured patients with psoriasis. Poster presentation, ISPOR, April 2021.

Dean R, Jensen IS, Cyr PL, Miller B, Maru B, Sproule DM, Feltner DE, et al. 2021. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Pol 9(1):1889841; doi: 10.1080/20016689.2021.1889841.

Alexander W, Jensen I, Hathway J, Srivastava K, Cyr P, Batt K. Economic IMPACT of utilizing eptacog beta for the on-demand treatment of bleeding events among hemophilia patients with inhibitors. Abstract PBI11, ISPOR 2021 Annual International Meeting.

Pang F, Dean R, Jensen I, Olaye A, Miller B. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Abstract PRO30, ISPOR 2021.

Chew D, Sacks NC, Emden MR, Preib MT, Cyr PL, Wood D, Pokorney SD. 2021. Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States. Am Heart J 233(March):132–140; doi: 10.1016/j.ahj.2020.12.012.

Sheshadri A, Healey B, Sacks N, Wu E, Cyr P, Boerner G, Huang H. 2021. Bronchiolitis obliterans syndrome following lung transplantation: Economic burden by chronic lung allograft dysfunction (CLAD) stage. J Heart Lung Trans 40(4-Sup):S70; doi: 10.1016/j.healun.2021.01.1913.

Hathway J, Miller-Wilson L, Yao W, Jensen I, Weinstein M, Parks P. 2021. The health economic impact of varying levels of adherence to colorectal screening on providers and payers. J Med Econ 24(1):69–78; doi: 10.1080/13696998.2020.1858607.

Niu X, Veeranki S, Dennen S, Liu Y, Shafrin J, Dembek C, Laubmeier K, Williams GR. Hospitalization risk among adults with bipolar I disorder treated with oral atypical antipsychotics: A long-term data analysis of Medicaid claims data. Abstract, CNS Spectrums 26(2):172-173, April 2021; doi: 10.1017/S1092852920002813.

Flythe JE, Hilliard TS, Ikeler K, Keller S, Gipson DS, Grandinetti AC, Nordyke RJ, Perrone RD, et al. 2020. Toward patient-centered innovation: A conceptual framework for patient-reported outcome measures for transformative kidney replacement devices. Clin J Am Soc Nephrol 15(10):1522-1530; doi: 10.2215/CJN.00110120. PMID: 32276947.

Sacks NC, Healey B, Cyr PL, Batt K, Henig NR. The economic burden of bronchiolitis obliterans syndrome (BOS) in allogenic hematopoietic stem cell transplant (alloHSCT) patients with Medicare coverage. Poster presentation, ISPOR 25th Annual International Meeting, Orlando, FL, May 2020.

Dean R, Arjunji R, Awano H, Igarash A^, Tanaka A, Jensen IS, Cyr PL et al. Cost-effectiveness of onasemnogene abeparvocec (ZOLGENSMA) for spinal muscular atrophy type 1 against nusinersen in Japan. ISPOR 25th Annual International Meeting, Orlando FL, 2020.

Sacks NC, Healey B, Cyr PL, Graham R. Economic burden of X-linked myotubular myopathy (XLMTM) by ventilation status. ISPOR 25th Annual International Meeting, Orlando FL, 2020.

Jensen IS, Hathway J, Cyr PL, Gauden D, Gardiner P. 2020. Cost–consequence analysis of ¹⁸F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Jena A, et al. 2020. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. J Med Econ 23(6):581-592; doi: 10.1080/13696998.2020.1730123.

Sacks NC, Cyr PL, Preib MT, Everson K, Wood DR, Raza S, Pokorney SD. 2020. Healthcare resource use and expenditures in patients newly diagnosed with paroxysmal supraventricular tachycardia. Am J Cardiol 125(2):215–221; doi: 10.1016/j.amjcard.2019.10.015.

Dean R, Miller B, Arjunji R, Feltner DE, Sproule DM, Jensen I, Dabbous O. Cost-utility analysis of single dose gene-replacement therapy for spinal muscular atrophy type 1 compared to chronic nusinersen treatment in Japan. Abstract PMU36, ISPOR 2020.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. Budget impact of improving adherence to colorectal cancer screening. Abstract PCN148, ISPOR 2020.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. The impact of increasing mt-sDNA use among colorectal cancer screeners in a US employer population. Abstract PCN145, ISPOR 2020.